NeuroPace Inc. Files Material Definitive Agreement 8-K

TL;DR

NeuroPace just signed a big deal, filing an 8-K to let everyone know.

AI Summary

On February 13, 2025, NeuroPace Inc. entered into a material definitive agreement. The company, headquartered at 455 N. Bernardo Avenue, Mountain View, CA, filed an 8-K report detailing this significant event.

Why It Matters

This filing indicates a significant new contract or partnership for NeuroPace Inc., which could impact its future operations and financial performance.

Risk Assessment

Risk Level: medium — Entering into a material definitive agreement is a significant event that could carry substantial implications, both positive and negative, for the company.

Key Numbers

• 20250213 — Report Date (The filing pertains to events on this date.)
• 22-3550230 — IRS Number (Company's Employer Identification Number.)

Key Players & Entities

• NeuroPace Inc. (company) — Registrant
• February 13, 2025 (date) — Date of earliest event reported
• 455 N. Bernardo Avenue, Mountain View, CA 94043 (address) — Principal executive offices
• 001-40337 (identifier) — SEC File Number

FAQ

Key Financial Figures

• $0.001 — ange on which registered Common Stock, $0.001 par value per share NPCE The Nasdaq

Filing Documents

• d848945d8k.htm (8-K) — 27KB
• 0001193125-25-026573.txt ( ) — 148KB
• npce-20250213.xsd (EX-101.SCH) — 3KB
• npce-20250213_lab.xml (EX-101.LAB) — 18KB
• npce-20250213_pre.xml (EX-101.PRE) — 11KB
• d848945d8k_htm.xml (XML) — 4KB

Forward Looking Statements

Forward Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act and Private Securities Litigation Reform Act made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "anticipates," "believes," "estimates," "expects," "forecasts," "intends," "may," "plans," "potential," "seeks," "will" and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements include, but are not limited to, statements regarding the completion of the Equity Offering, the satisfaction of customary closing conditions related to the Equity Offering and Stock Repurchase and the planned use of the net proceeds from the Equity Offering to effect the Stock Repurchase. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, risks and uncertainties associated with the consummation of the Equity Offering and Stock Repurchase, the completion of the Equity Offering and Stock Repurchase on the anticipated terms or at all, uncertainties related to market conditions, the satisfaction of customary closing conditions related to the Equity Offering and Stock Repurchase, and general economic conditions. These and other risks and uncertainties include those described more fully in the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the Company's public filings with the Securities Exchange Commission (the "SEC'), including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, filed with the SEC on November 12, 2024, as well as any other reports that it ma

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NeuroPace, Inc. Dated: February 14, 2025 By: /s/ Rebecca Kuhn Rebecca Kuhn Chief Financial Officer and Vice President, Finance and Administration

View Full Filing

View this 8-K filing on SEC EDGAR